Moores Cancer Center

La Jolla, California 92093-0820

4 studies enrolling now · 13 studies all time

What they study most

Abiraterone Acetate, Advanced Breast Cancer, Advanced Cancer, Advanced Ovarian Cancer, Advanced Solid Tumor, Androgens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, B-Cell Chronic Lymphocytic Leukemia (B-CLL), Breast Cancer, Breast Neoplasms, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative

Studies at this site

• A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer — Recruiting now
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) — Recruiting now
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer — Recruiting now
• A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors — Recruiting now
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Running, not enrolling
• A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) — Running, not enrolling
• (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma — Running, not enrolling
• IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma — Running, not enrolling
• Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer — Completed
• Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) — Stopped early
• A Study of BMS-986148 in Patients With Select Advanced Solid Tumors — Stopped early
• Circulating Tumor Cells in Non-Small Cell Lung Carcinoma — Completed
• Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia — Completed